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Highly glycolytic cancer cells prevent intracellular
acidification by excreting the glycolytic end-prod-
ucts lactate and H+ via the monocarboxylate trans-
porters 1 (MCT1) and 4 (MCT4). We report that
syrosingopine, an anti-hypertensive drug, is a dual
MCT1 and MCT4 inhibitor (with 60-fold higher po-
tency on MCT4) that prevents lactate and H+ efflux.
Syrosingopine elicits synthetic lethality with metfor-
min, an inhibitor of mitochondrial NADH dehydroge-
nase. NAD+, required for the ATP-generating steps
of glycolysis, is regenerated from NADH by mito-
chondrial NADH dehydrogenase or lactate dehydro-
genase. Syrosingopine treatment leads to high
intracellular lactate levels and thereby end-product
inhibition of lactate dehydrogenase. The loss of
NAD+ regeneration capacity due to combined met-
formin and syrosingopine treatment results in glyco-
lytic blockade, leading to ATP depletion and cell
death. Accordingly, ATP levels can be partly restored
by exogenously provided NAD+, the NAD precursor
nicotinamide mononucleotide (NMN), or vitamin K2.
Thus, pharmacological inhibition of MCT1 and
MCT4 combined with metformin treatment is a po-
tential cancer therapy.INTRODUCTION
A hallmark of cancer is a global metabolic shift toward
increased glycolysis (Potter et al., 2016). Transformed cells
preferentially produce ATP via glycolysis of glucose to lactate.
As glycolysis is less efficient than oxidative phosphorylation for
ATP generation, cancer cells increase glucose uptake and the
glycolytic rate to compensate. This leads to excess lactate pro-
duction that can cause intracellular acidification. Cytosolic
acidification, in turn, reduces the glycolytic rate via inhibition
of the rate-limiting enzyme PFK1 (Trivedi and Danforth, 1966).Cell Repo
This is an open access article undThus, cells require the efflux of lactate and H+ to prevent intra-
cellular acidification and to sustain continuously high rates of
glycolysis.
The bi-directional monocarboxylate transporters (MCTs)
perform H+-linked transport of L-lactate across the plasma
membrane (Halestrap, 2013). Four MCTs are known to transport
lactate. MCT1 is ubiquitously expressed and has a high affinity
for lactate (3–6 mM). It is the main lactate exporter under normal
conditions where intracellular lactate levels are low. Its high affin-
ity for lactate also allows it to import circulating lactate (e.g., in
liver where lactate is used for hepatic gluconeogenesis). Some
cancers utilize lactate as a metabolic fuel (Faubert et al., 2017;
Sonveaux et al., 2008). In solid tumors, zonation of oxygen avail-
ability gives rise to tumor symbiosis where lactate excreted by a
hypoxic inner core is taken up and used by tumor cells at the vas-
cularized tumor periphery (Allen et al., 2016; Jime´nez-Valerio
et al., 2016; Pisarsky et al., 2016). In these situations, lactate
import by MCT1 supports tumor growth. MCT2 is expressed in
brain, liver, and renal tubules. MCT3 is expressed in the choroid
plexus and retina. Both MCT2 and MCT3 are poorly studied.
MCT4 expression is induced by hypoxia via hypoxia-inducible
factor 1 alpha (HIF-1a) (Ullah et al., 2006) and is thus of particular
interest in cancer. MCT4 is a marker for poor prognosis in multi-
ple cancers (Baek et al., 2014). MCT4 has a low affinity for lactate
(25–30mM) and does not import serum lactate (normally <2mM).
Thus, MCT4 appears to be dedicated for lactate export under
conditions of high intracellular lactate.
MCT inhibition is a potential therapeutic target in cancer.
Pharmacological or genetic ablation of MCT1 or MCT4 activity
leads to reduced proliferation in vitro and in vivo (Le Floch
et al., 2011). The anti-proliferative effect of MCT ablation can
be augmented with the biguanides metformin and phenformin
(Granja et al., 2015; Marchiq et al., 2015). The only effective
small-molecule MCT inhibitors developed to date are specific
to MCT1, with one drug (AZD3965) currently in clinical trials.
However, AZD3965 is ineffective when MCT4 is expressed
(Polanski et al., 2014), thus restricting its application to tumors
that are MCT4. There has been considerable effort in devel-
oping a pan-MCT or MCT4-specific inhibitor due to its potential
utility in cancer therapy, but such efforts have not been
successful.rts 25, 3047–3058, December 11, 2018 ª 2018 The Authors. 3047
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
We report that syrosingopine inhibits MCT1 and MCT4. We
previously described synthetic lethality between syrosingopine
and metformin (Benjamin et al., 2016) and now show that this
synthetic lethal interaction is due to dual MCT1 and MCT4 inhi-
bition by syrosingopine. Mitochondrial complex I (an NADH de-
hydrogenase) and lactate dehydrogenase (LDH) are the main
cellular sources for regenerating NAD+ required for glycolysis.
The direct inhibition of mitochondrial NADH dehydrogenase by
metformin, together with the end-product inhibition of LDH due
to elevated lactate levels arising from syrosingopine treatment,
leads to reduced NAD+ levels. Supplementing NAD+ or
increasing endogenous NAD levels with its precursor nicotin-
amide mononucleotide (NMN) restores ATP levels and delays
cell lethality, suggesting that an impaired NAD+ regenerating ca-
pacity may be the underlying mechanism of synthetic lethality.
The identification of syrosingopine as a dual MCT1/4 inhibitor
can serve as a starting point for further development within this
target class. Thus, the rational combination of metformin with
syrosingopine, or similar entities with dual MCT1 and MCT4
inhibitory properties, holds promise as an anti-cancer therapy.
RESULTS
Syrosingopine Causes Intracellular Lactate
Accumulation and Acidification
Synthetic lethality elicited by the combination of metformin with
syrosingopine is accompanied by a decrease in glycolysis, as
measured by a drop in ATP and extracellular lactate levels
(Benjamin et al., 2016). To further investigate this link, intra-
and extra-cellular lactate levels were measured in HeLa cells
treated with syrosingopine and various inhibitors of glycolysis
and oxidative phosphorylation. We also included reserpine, the
parent molecule of syrosingopine, and two novel syrosingopine
derivatives F3-syro and SyroD (Figure S1A). Metformin was
able to elicit synthetic lethality with the following molecules, in
order of decreasing potency: F3-syro, syrosingopine, and reser-
pine (Figure S1B). Reserpine was previously shown to be less
potent than syrosingopine (Benjamin et al., 2016). SyroD, a cyto-
toxic derivative of syrosingopine, was unable to elicit synthetic
lethality with metformin (Figure S1C).
As expected, extracellular lactate levels decreased after
glycolysis was inhibited by oxamic acid (OMA) and NaF, which
inhibit LDH and enolase, respectively (Figure 1A). Conversely,
treatment with inhibitors of oxidative phosphorylation (antimycin
A andmetformin) increased extracellular lactate levels due to the
compensatory upregulation of glycolysis upon inhibition of mito-
chondrial respiration. Within the syrosingopine compound fam-
ily, extracellular lactate levels were reduced by syrosingopine
and F3-syro, and the magnitude of reduction correlated with
the ability to elicit synthetic lethality. Reserpine and SyroD had
no effect on extracellular lactate levels.
Intracellular lactate levels weremeasured in the same samples
(Figure 1A). OMA and NaF reduced lactate levels due to the inhi-
bition of glycolysis. The inhibition of oxidative phosphorylation
by antimycin A andmetformin did not greatly elevate intracellular
lactate levels, indicating, in light of the corresponding increase in
extracellular lactate, that the additional lactate generated by
increased glycolysis is mostly exported out of the cell. Surpris-3048 Cell Reports 25, 3047–3058, December 11, 2018ingly, syrosingopine and F3-syro caused a large increase in intra-
cellular lactate levels. No substantial increase was observed with
the reserpine or SyroD treatment. Intracellular acidification from
lactate accumulation was detectable 3 hr after the addition of
syrosingopine and F3-syro (Figure 1B). Accumulation of intracel-
lular lactate by syrosingopine and F3-syro was detectable after
1 hr (Figure 1C) and peaked at 4 hr. The effect was concentration
dependent, with F3-syro being more potent than syrosingopine
(Figure 1D). Notably, within the compound family, the same
hierarchy (F3-syro > syrosingopine > reserpine) was seen for
intracellular lactate accumulation and metformin-dependent
synthetic lethality, suggesting a possible link.
To determine if intracellular lactate accumulation could be re-
produced in vivo, we used a liver tumor mouse model (Hindupur
et al., 2018), in which syrosingopine-metformin was previously
shown to prevent tumor development (Benjamin et al., 2016).
Serum lactate levels were significantly reduced in syrosingo-
pine-treated mice (Figure 1E). The intracellular lactate from liver
tumor nodules was measured in the same mouse cohort. Higher
lactate levels were detected in syrosingopine-treated mice (Fig-
ure 1F). Collectively, these data suggest that syrosingopine-
treated tumor cells sequester lactate.
Syrosingopine and F3-syro Inhibit the Lactate
Transporters MCT1 and MCT4
Accumulation of intracellular lactate was concomitant with
reduced extracellular lactate and pointed to a defect in lactate
export. Human HAP1 cells were deleted for either MCT1 or
MCT4 and target gene knockout was confirmed by immunoblot-
ting (Figure S2A). Clones lacking MCT2 expression were
selected. Intracellular lactate levels after treatment with syrosin-
gopine, F3-syro, and a MCT1-specific inhibitor ARC155858 (AR)
showed intracellular lactate accumulation in MCT1 knockout
(MCT1-KO) cells treated with syrosingopine and F3-syro, indi-
cating that these compounds inhibit MCT4-driven lactate export
(Figures 2A and 2D). As expected, the addition of ARC155858
had no effect on lactate transport in the MCT1-KO due to the
absence of the drug target. In MCT4-KO cells, ARC155858
induced lactate accumulation via inhibition of MCT1 (Figures
2B and 2E). Syrosingopine and F3-syro treatments also resulted
in lactate accumulation in MCT4-KO, indicating that they also
inhibit MCT1 in addition to MCT4. Syrosingopine is around
60-fold more potent against MCT4 (half maximal inhibitory
concentration [IC50], 40 nM; Figure 2D) than MCT1 (IC50,
2500nM; Figure 2E). ARC155858 is highly potent against
MCT1 (IC50, 7 nM; Figure 2E) but has essentially no activity
against MCT4 (Figure 2D). Parental HAP1 cells utilize both
MCT1 and MCT4 for lactate export. ARC155858 causes lactate
accumulation in wild-type cells but to a lower extent than syro-
singopine or F3-syro (Figures 2C and 2F), suggesting only partial
impairment of lactate transport via MCT1-specific inhibition.
These data indicate that syrosingopine and F3-syro inhibit both
MCT1 and MCT4, with greater potency against MCT4.
Lactate Efflux by MCT1 and MCT4 Is Inhibited by
Syrosingopine and F3-syro
A lactate chase experiment using radioactively labeled lactate
was performed to measure lactate export and the effect of
Figure 1. Syrosingopine Causes Intracellular Lactate
(A) HeLa cells were treated for 3 hr with the indicated drugs, and extracellular or intracellular lactate levels were measured (syrosingopine, F3-syro, SyroD,
reserpine, 10 mM; antimycin A [Ant], 0.5 mM; metformin, 5mM; oxamic acid [OMA], 20 mM; NaF, 5 mM).
(B) Intracellular pH in drug-treated (10 mM, 3 hr) HeLa cells stained with pHrodo (n = 5).
(C) Rate of extra-or intra-cellular lactate accumulation in HeLa cells treated with indicated drugs (10 mM).
(D) Dose-dependent increase in intracellular lactate levels in response to syrosingopine and F3-syro. HeLa cells were treated for 3 hr.
(E) Serum lactate levels in mice treated with syrosingopine.
(F) Intracellular lactate levels in liver tumor nodules excised from vehicle and syrosingopine treated mice.
Each experiment was performed twice in (A)–(D). Data are presented as mean ± SEM.drug treatment. Cells were pulse-labeled with 3H-L-lactate, fol-
lowed by pelleting and re-suspension in label-free medium (Fig-
ure S3A). The rate of lactate efflux was determined bymeasuring
the amount of radioactivity retained in the cell pellet or exported
to the medium at appropriate time points. Where required, the
drug of interest was added during the labeling and post-wash
steps.
In MCT4-KO HAP1 cells, lactate efflux from DMSO-treated
cells was rapid and essentially complete after 60 min (Figure 3A).
Treatment with the MCT1-specific inhibitor ARC155858 blocked
lactate efflux as expected, thus validating the assay. Treatment
with syrosingopine and F3-syro slowed lactate efflux, with the
majority of the label retained in the cell pellet even after
120 min, thus providing direct evidence for MCT1 inhibition by
these compounds.
In MCT1-KO cells, treatment with the MCT1-specific inhibitor
ARC155858 had no effect on lactate efflux due to the absence of
the drug target (Figure 3B). Treatment with syrosingopine and
F3-syro slowed lactate efflux, with the majority of the label re-
tained in the cell pellet after 60 min, thus demonstrating that
these compounds inhibit MCT4.HAP1 cells were derived from haploid KBM7 cells that were
selected for adherence in tissue culture conditions. To investi-
gate the effect of these drugs in a less manipulated cell back-
ground, we screened a panel of well-characterized cancer cell
lines for MCT1 and MCT4 expression (Figure S2B). Most cell
lines express both transporters, but we identified OPM2 and
K562 as being MCT1+ MCT4, SkBr3 as being MCT1
MCT4+, and MDA-MB-453 as double negative (MCT1
MCT4). The CD147 chaperone is required for proper folding,
translocation, and function of the lactate transporters at the
plasma membrane (Kirk et al., 2000) and was present in all the
cell lines. We selected HL60 (MCT1+ MCT4+), K562 (MCT1+
MCT4), SkBr3 (MCT1 MCT4+), and MDA-MB-453 (MCT1
MCT4) as a cell panel comprising all possible combinations
of MCT1 and MCT4 expression. To gauge relative MCT expres-
sion levels within the cell panel members, immunodetection of
all 4 MCT isoforms was performed on the same blot (Fig-
ure S2C). MCT2 was expressed in HL60 and MDA-MB-453,
while MCT3 was strongly expressed in MDA-MB-453 and at
much lower levels in K562 and SkBr3. Comprehensive determi-
nation of the expression profile for all the MCT isoforms thusCell Reports 25, 3047–3058, December 11, 2018 3049
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Figure 2. Intracellular Lactate Accumulation Is due to Inhibition of the Lactate Transporters MCT1 and MCT4 by Syrosingopine
(A–C) Intracellular lactate accumulation in HAP1 cells deleted for MCT1 (A), MCT4 (B), and HAP1 wild-type cells (C) following treatment with ARC155858 (1 mM),
syrosingopine (10 mM), or F3-syro (10 mM).
(D–F) Dose-responsive increase in intracellular lactate in HAP1 cells deleted for MCT1 (D), MCT4 (E), and HAP1 wild-type cells (F) treated with ARC155858,
syrosingopine, and F3-syro for 2 hrs. Each assay was performed twice and a representative experiment is shown. Data points performed in duplicate and
presented as mean ± SEM.revealed thatMDA-MB-453 relies onMCT2 andMCT3 for lactate
transport, whereas K562 and SkBR3 are mainly reliant on
MCT1 and MCT4, respectively. HL60 expressed MCT1, MCT2,
and MCT4.
The cell panel was then tested for responsiveness to the com-
bination ofmetforminwith syrosingopine or F3-syro (Figure S1B).
Synthetic lethality was elicited in HL60, K562, and SkBr3 but not
in MDA-MB-453. Efficacy in HL60 suggests that syrosingopine
and F3-syro inhibit MCT1, MCT2, and MCT4. MDA-MB-453
was resistant to the drug combination, indicating that MCT3,
which is highly overexpressed only in MDA-MB-453, is not tar-
geted by syrosingopine and F3-syro.
Extra- and intra-cellular lactate levels in response to syrosin-
gopine and F3-syro were measured in HL60 (Figure S2D) and
were similar to those previously observed in HeLa cells (Fig-
ure 1A). Consequently, we used HL60 to investigate the effect
of syrosingopine and F3-syro in the radioactive lactate efflux
assay. Syrosingopine and F3-syro strongly retarded lactate
efflux, with almost all label retained in the cell at the experi-
mental endpoint (Figure 3C). In contrast, inhibition of MCT1 by
ARC155858 did not impede lactate export as MCT2 and MCT4
could compensate for loss of MCT1 activity. Therefore inhibition
of lactate transport by syrosingopine and F3-syro in HL60 sug-3050 Cell Reports 25, 3047–3058, December 11, 2018gests simultaneous inhibition of MCT1, MCT2, and MCT4 by
these drugs.
Lactate Import and Export Are Affected Differently by
Syrosingopine and F3-syro
As shown in Figure 3C (0-min time points), lactate uptake was
higher in syrosingopine- and F3-syro-treated HL60 cells than
in the DMSO control. We repeated labeling of HL60 cells with
3H-L-lactate in the presence of the respective drugs and
measured radioactivity in the pellet immediately after the pulse.
Lactate transport is bi-directional, and the incorporation at
the end of the pulse represents the equilibrium between radio-
label uptake and re-export into the medium (Figure S3B).
Lactate uptake was reduced by ARC155858 due to the potent
inhibition of MCT1, which is the only isoform that efficiently
imports lactate (Figure S4A). However, syrosingopine- and
F3-syro-treated cells again displayed increased lactate uptake
relative to the DMSO control. Thus, the net effect of the syro-
singopine-like drugs acting on both MCT1 and MCT4, after
allowing for lactate import and export to reach equilibrium, is
to increase the accumulation of labeled lactate in the cell.
This seemingly paradoxical accumulation of lactate can be ex-
plained if lactate import is less potently inhibited than lactate
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Figure 3. Syrosingopine Inhibits Lactate Efflux
by MCT1 and MCT4
Lactate export assays showing amount of radio-
labeled lactate (cpm) retained in the cell pellet versus
label released into the medium over a time course for
HAP1 MCT4-KO cells pre-treated with indicated
drugs (syrosingopine, 10 mM; F3-syro, 1 mM; and
ARC155858, 10 mM) (A). Similar assays were per-
formed for HAP1 MCT1-KO cells (B) and HL60 cells
(C). Each assay was performed at least twice and a
representative experiment is shown.
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Figure 4. Syrosingopine Interacts Directly with MCT1 and MCT4
(A) Schematic representation of human MCT1 and MCT4 proteins. Epitopes
detected by the antibody in red.
(B) DARTS assay from HCT116 cell extracts. Cells were incubated with the
indicated compounds (syrosingopine, 10 mM; F3-syro, 10 mM; SyroD, 10 mM;
and ARC155858, 10 mM) and lysates subjected to limiting thermolysin diges-
tion. Resulting fragments were probed with antibodies against MCT1, MCT4,
CD147, and b1-integrin as control (asterisk indicates protected fragment).
(C) Co-immunoprecipitation from HL60 cells treated with DMSO or syr-
osingopine (5 mM, 16 hr). The CD147 chaperone was immunoprecipitated and
co-IP ofMCT1 andMCT4was determined by immunoblotting (WCL, whole cell
lysate).
(D) Levels of CD147, MCT1, and MCT4 proteins in HL60 cells treated for 24 hr
with syrosingopine (5 mM).
3052 Cell Reports 25, 3047–3058, December 11, 2018export, resulting in a net accumulation of exogenous label in
the cell.
In K562 cells that only express MCT1, ARC155858 reduced
lactate uptake that is consistent with the inhibition of lactate
import by MCT1 (Figure S4B). However, net lactate uptake was
increased by syrosingopine in K562, indicating that the effect
of syrosingopine is greater on lactate export than import in
MCT1. These data collectively show that syrosingopine and
F3-syro have a different impact on the rate of import and export
in the lactate transporters.
Syrosingopine and F3-syro BindMCT1 andMCT4 In Vitro
Drug Affinity Responsive Target Stability (DARTS) was used to
investigate possible binding between the syrosingopine class
drugs and the MCTs (Lomenick et al., 2009). Human HCT116
colorectal carcinoma cells were incubated with the drug of inter-
est prior to harvest, and membrane extracts were subjected to
limiting proteolytic digestion by thermolysin in the presence of
the respective drug. Probing for MCT1 resulted in the detection
of protected fragments (18, 28 kDa) in ARC155858-incubated
extracts compared to the DMSO control (Figures 4A and 4B)
and indicate possible exposed cleavage sites in the intracellular
loop (ARC155858 binds MCT1 intracellularly at loops 7–10)
(Ovens et al., 2010). Incubation with syrosingopine or F3-syro
yielded protected fragments of comparable size as those
observed with the ARC155858 treatment (Figure 4B), providing
evidence that these compounds interact with MCT1 in vitro.
The same lysates were probed for MCT4, but there was no evi-
dence for the protection of MCT4 from proteolytic digestion by
ARC155858. However, syrosingopine and F3-syro treatment
reduced the proteolytic cleavage of a 37-kDa fragment, sug-
gesting drug binding to MCT4. Notably, the SyroD derivative
that is unable to elicit synthetic lethality with metformin also
did not confer any protection from proteolytic digestion to
MCT1 or MCT4. The MCT4-interacting protein b1-integrin and
CD147 either showed non-specific digestion or no digestion at
the concentration of thermolysin used and served as internal
controls for digestion and protein levels. Overall, these data pro-
vide evidence of a direct interaction between syrosingopine and
F3-syro with MCT1 and MCT4.
A consequence of drug binding to the lactate transportersmay
be the disruption of active CD147-MCT complexes. Immunopre-
cipitation of CD147 showed no change in the association of
MCT1 or MCT4 with CD147 upon syrosingopine treatment
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Figure 5. Dual MCT1 and MCT4 Inhibition Is
Necessary to Kill Cancer Cells
(A and B) Survival curve of HAP1 MCT1-KO cells with
increasing concentrations of syrosingopine (S; in A)
and the MCT1 inhibitor ARC155858 (AR; in B). Both
drugs were also titrated in the presence of a sub-lethal
concentration ofmetformin (M, 4mM) to elicit possible
synthetic lethality.
(C and D) Survival curve for HAP1 MCT4-KO cells
treated with syrosingopine (C) and ARC155858 (D).
(E–H) Human cancer cell lines comprising all combi-
nations of MCT1 and MCT4 expression. HL60 (E),
K562 (F), SkBr3 (G), and MDA-MD-453 (H) were
titrated with increasing concentrations of ARC155858
in the presence of sub-lethal concentrations of
metformin (4 mM) or syrosingopine (0.5 mM). Cell
proliferation and survival was measured after 3 days.
All data points are in triplicate and presented as
mean ± SEM.(Figure 4C). Prolonged syrosingopine treatment also did not
result in a decrease in levels of CD147 or either MCT (Figure 4D).
These data support a view that syrosingopine inhibits MCT func-
tion directly and not indirectly via an effect on complex formation
or stability.
Inhibition of Lactate Transport Is Required for Synthetic
Lethality between Syrosingopine and Metformin
Syrosingopine inhibits the vesicular monoamine transporter
(Schuldiner et al., 1993); nevertheless, vesicular monoamine
transporter (VMAT) inhibition is unrelated to synthetic lethality
with metformin (Benjamin et al., 2016). To determine if lactate
transport inhibition is responsible for synthetic lethality, HAP1
MCT KO cells were titrated with syrosingopine or ARC155858
in the presence/absence of a non-lethal concentration of metfor-Cell Repmin (effect of metformin alone is shown
in Figure S5A). Synthetic lethality was
induced by the syrosingopine-metformin
combination in HAP1 MCT1-KO (Figure 5A).
As expected, the MCT1-specific inhibitor
ARC155858 had no effect regardless of the
presence of metformin due to absence of
its target (Figure 5B).
Synthetic lethality was induced by syro-
singopine-metformin in HAP1 MCT4-KO
(Figure 5C). MCT4-KO cells were more sen-
sitive to ARC155858 due to their reliance
solely on MCT1 for lactate transport. Never-
theless, MCT1 inhibition, even when it is the
only lactate transporter present, was not le-
thal even at high ARC155858 concentrations
but only resulted in reduced cell proliferation
(Figure S5B). Instead, MCT1 inhibition by
ARC155858 required simultaneous treat-
ment with metformin to elicit lethality (Fig-
ures 5D and S5B).
The response to syrosingopine and
ARC155858 was studied in further detail byusing the cell panel. In HL60, ARC155858 had no effect on
growth or survival even in the presence of metformin (Figure 5E),
showing that MCT2 and MCT4 are able to compensate for the
loss of MCT1 activity. Nonetheless, adding in a low, sub-lethal
concentration of syrosingopine to the ARC155858-metformin
combination was able to potentiate cell killing, demonstrating
that combined MCT1, MCT2, and MCT4 inhibition is absolutely
required to elicit cell death. Note that syrosingopine and metfor-
min were used at concentrations where they had aminimal effect
on HL60 growth (Figure S5C, and for the other cell lines in the
panel). K562 mimicked the results seen in HAP1MCT4-KO cells.
ARC155858 inhibited K562 growth, but lethality was induced
only after the addition of metformin (Figure 5F) and increased
with the further addition of syrosingopine. Similarly, SkBr3
mimicked the HAP1 MCT1-KO model. SkBr3 proliferation wasorts 25, 3047–3058, December 11, 2018 3053
unaffected by ARC155858, as expected due to the absence of
MCT1, and lethality could not be induced with the addition of
metformin (Figure 5G). Increasing the amount of syrosingopine
elicited syrosingopine-metformin synthetic lethality, as seen
earlier in Figure S1B, but in no case did titrating in higher
amounts of ARC155858 result in a dose-dependent increase in
cell killing. In MDA-MB-453, ARC155858 had no effect on
growth, and the further addition of metformin, or metformin
with syrosingopine, was unable to elicit synthetic lethality
(Figure 5H).
Collectively, the results from the cell panel, in light of their MCT
isoform expression profile (Figure S2C), support the view that the
induction of synthetic lethality by syrosingopine with metformin
is due to its role as a dual MCT1 and MCT4 inhibitor (while the
HL60 results suggest that syrosingopine also inhibits MCT2,
there is only direct evidence for MCT1 and MCT4 inhibition
from the lactate transport assays). These results (Figures 5A–
5H) also demonstrate that the inhibition of lactate transport by
itself is not cytotoxic and is lethal only with the concomitant inhi-
bition of oxidative phosphorylation. Furthermore, when MCT4 is
expressed, MCT1 inhibition alone is unable to elicit cell death
even when oxidative phosphorylation is inhibited by metformin,
thus demonstrating the advantage of combined MCT1 and
MCT4 inhibition.
The potential of metformin as an anti-cancer therapy may be
hampered by inadequate dosing in clinical settings (Chandel
et al., 2016; Dowling et al., 2016; Kordes et al., 2015). Metformin
was titrated in HL60 against varying concentrations of syrosin-
gopine and ARC155858 to determine the lowest effective con-
centration of metformin required for cell killing in vitro (Figures
S5D and S5E). ARC155858 (20 nM) together with syrosingopine
(1 mM) was able to reduce the metformin IC50 to 0.9 mM
(Figure S5F).
Syrosingopine and Metformin Induce Energy Crisis due
to NAD+ Depletion
The accumulation of intracellular lactate does not lead to cell
death, as treatment with syrosingopine or ARC155858 is only
cytostatic. This result led us to consider the role of NAD+/
NADH in cellular energy generation. NAD+ is reduced to NADH
during glycolysis, and a constant supply of NAD+ is required to
sustain a continuous high rate of glycolysis (Figure 6A). NAD+
is regenerated from NADH via the conversion of pyruvate to
lactate by LDH. LDH is end-product inhibited by high lactate
concentrations (Stambaugh and Post, 1966). The other major
route for NAD+ regeneration is via mitochondrial complex I, the
target of metformin. The simultaneous inhibition of LDH and
complex I thus results in a loss of the NAD+ regenerating capac-
ity that could lead to NAD+ depletion and glycolytic blockade.
LDH inhibition by OMA was shown to be synthetic lethal with
phenformin (Miskimins et al., 2014). We observed synthetic
lethality between OMA and metformin in HL60 (Figure S6A) but
not between OMA and syrosingopine, supporting the idea that
OMA and syrosingopine act on the same arm of the synthetic le-
thal interaction, namely via LDH inhibition.
The NAD+/NADH ratio is a key indicator of cellular health, and
a drop in the ratio in response to drug treatment correlates with
lower cell proliferation (Gui et al., 2016). Total NAD (NAD+ and3054 Cell Reports 25, 3047–3058, December 11, 2018NADH) and NADH levels were determined in HL60 treated with
syrosingopine, metformin, or in combination. Cells were treated
acutely for 8 hr and measurements taken before the onset of cell
death arising from syrosingopine-metformin treatment. No sig-
nificant reduction in cell number or viability was observed by try-
pan blue staining and automated counting (Figure S6B). Total
NAD (NADt) levels were significantly lower after syrosingopine-
metformin treatment (Figure 6B). This was due to the loss of
NAD+, as reflected by a drop in theNAD+/NADH ratio (Figure 6C)
and was concomitant with reduced ATP levels (Figure S6C).
NAD levels can be boosted by supplementation with its pre-
cursor NMN (Yoshino et al., 2018). Preliminary experiments
showed that syrosingopine-metformin-treated HL60 cells grown
inmedium supplementedwith NMNhad a partial recovery in ATP
levels (Figure S6D), with similar observations in cells supple-
mented with NAD+ (Figure S6E). ATP levels were measured in
cells treated with syrosingopine-metformin for 30 hr (Figure 6D).
High NMN and NAD+ concentrations were needed to counter
the effect of syrosingopine-metformin treatment, and this had
an impact on growth even in the DMSO controls, but neverthe-
less, both NMN and NAD+ were able to restore ATP levels after
syrosingopine-metformin treatment. HL60 cells start to undergo
apoptosis after 24 hr of syrosingopine-metformin treatment
(Benjamin et al., 2016) and have a rough, shrunken appearance.
However, syrosingopine-metformin-treated cells in the presence
of NMN showed less visible signs of damage, indicating a delay
in cell death (Figure 6E).
NAD+ levels can be artificially increased by supplementation
with quinones, such as vitamin K2 (menaquinone). The reduction
of exogenous quinones by cytoplasmic oxidoreductases is
coupled with the oxidation of NADH to NAD+ and provides a
temporary boost in NAD+ levels before quinone depletion.
HL60 cells treated with syrosingopine and metformin show a
slight decrease in ATP levels after 8 hr. ATP levels are partially
restored in a dose-dependent fashion by exogenous vitamin
K2 (Figure 6F).
Collectively, these data support the hypothesis that NAD+
depletion is responsible for synthetic lethality induced by syro-
singopine-metformin treatment.
DISCUSSION
We show direct evidence that syrosingopine is a dual inhibitor of
the lactate transportersMCT1 andMCT4. Furthermore, we show
that dual inhibition ofMCT1 andMCT4 accounts for the synthetic
lethality of syrosingopine in combination with metformin in hu-
man cancer cells.
The MCTs are important for cancer cell growth and survival
(Doherty and Cleveland, 2013), and accordingly, a lot of effort
has been invested in developing lactate transporter inhibitors
as potential anti-cancer agents. Several MCT1-specific inhibi-
tors have been developed (Guile et al., 2006), with one
(AZD3965) in phase I clinical trials for advanced cancer. The
disadvantage of MCT1-specific inhibition is that it is ineffective
when MCT4 is expressed. This is a particularly severe limitation,
as MCT4 expression is induced by hypoxia in the majority of tu-
mors. There are no reports of an effective small molecule inhib-
itor for MCT4. Pouysse´gur and colleagues have alluded to an
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Figure 6. Syrosingopine-Metformin Lethality Can Be Rescued with Exogenous NAD+
(A) Schematic representation of the main branches of the glycolytic pathway.
(B) Total NAD (NADt) and NADH levels in HL60 after metformin (4 mM) or syrosingopine (5 mM) treatment for 8 hr.
(C) NAD+/NADH ratio of HL60 cells in (B).
(D) ATP levels measured in HL60 cells after 30 hr of treatment with metformin (4 mM) or syrosingopine (5 mM) and parallel treatment in the presence of NMN
or NAD+.
(E) Micrographs of HL60 cells treated as in (D). Scale bar represents 100 mm.
(F) ATP levels in HL60 cells treated with metformin (4 mM) or syrosingopine (5 mM) for 8 hr and with the addition of vitamin K2. All experiments were performed
twice. Data points were performed in duplicate and presented as mean ± SEM. RLU, relative light units.MCT4-specific inhibitor, AZ93 (Marchiq and Pouysse´gur, 2016).
However, similar to MCT1-specific inhibitors, this compound is
ineffective in cells expressing both MCT1 and MCT4 due to thefunctional redundancy of the transporters. Acriflavine was
recently reported to disrupt the MCT4-CD147 interaction (but
not MCT1-CD147), but this had no effect on lactate secretionCell Reports 25, 3047–3058, December 11, 2018 3055
(Voss et al., 2017). We see no evidence that syrosingopine dis-
rupts the interaction between MCT1 or MCT4 and CD147;
instead, syrosingopine appears to interact directly with the
transporters (Figure 4). Diclofenac was shown to prevent lactate
uptake by MCT4 in a Xenopus oocyte lactate transport assay
(Sasaki et al., 2016); however, its inhibitory effect on lactate
uptake in human Caco-2 cells is unclear, as MCT isoform
expression was not characterized. We show direct biochemical
evidence that syrosingopine inhibits lactate transport by MCT1
andMCT4. In addition, synthetic lethality between syrosingopine
andmetformin in a cell panel comprising various combinations of
MCT1-4 isoform expression suggests that syrosingopine is also
able to inhibit MCT2 but is inactive against MCT3.
How does syrosingopine in combination with metformin elicit
synthetic lethality? Under physiological conditions, the reduc-
tion of pyruvate to lactate by LDH is favored and serves to
regenerate NAD+ consumed upstream in the ATP-producing
steps of the glycolytic pathway (Figure 6A). Lactate accumula-
tion upon MCT inhibition leads to high intracellular lactate con-
centrations that can result in end-product inhibition of LDH and,
consequently, loss of NAD+ regenerating capacity. The simulta-
neous inhibition by metformin of mitochondrial complex I, the
other main source of NAD+ regeneration, results in a decrease
in the NAD+/NADH ratio, loss of glycolytic ATP production, and
cell death. The observation that ATP levels can be partly
restored by exogenous NAD+ or the NAD precursor NMN sug-
gests that the cause of synthetic lethality is NAD+ depletion.
This rescue requires supra-physiological concentrations of
NAD+ and NMN, which may be due to the poor permeability
of these compounds in HL60 cells (Billington et al., 2008). We
note that NAD+ and NMN are unable to prevent cell death after
48 hr of syrosingopine-metformin treatment (data not shown).
The lack of NAD+ to fuel glycolysis is a plausible reason for syr-
osingopine-metformin synthetic lethality. This is reminiscent of
the situation in DNA-damaged cells where activated PARP1
consumes excessive amounts of NAD+ (Ying et al., 2005), lead-
ing to cell death. Vitamin K2 partially rescues ATP production in
syrosingopine-metformin-treated cells. Exogenous vitamin K2
gives a temporary boost in NAD+ levels that transiently sup-
ports glycolysis despite syrosingopine-metformin treatment.
The rescue is short-lived due to the depletion of exogenous
vitamin K2 and the absence of NAD+/NADH-regenerating
mechanisms, which unfortunately precludes the opportunity of
studying an effect on cell proliferation. Nevertheless, it provides
supporting evidence for the proposed mechanism of synthetic
lethality.
Syrosingopine, as a dual MCT1 and MCT4 inhibitor, may have
additional anti-tumor benefits in vivo. Most of the lactate
secreted by cancer cells accumulates in the extracellular space,
creating a tumor microenvironment that promotes cell invasion
and metastasis (Kato et al., 2013). Extracellular acidification by
lactate also has an immunosuppressive effect on tumor-infil-
trating immune cells (Brand et al., 2016; Fischer et al., 2007).
Functional differentiation in some tumors into highly glycolytic
hypoxic cores surrounded by well-vascularized outer regions
results in metabolic symbiosis where lactate generated as a
waste product in the hypoxic core is utilized as a fuel by nor-
moxic cancer cells at the tumor periphery. Tumor cells can3056 Cell Reports 25, 3047–3058, December 11, 2018also utilize lactate originating from surrounding stromal cells
(the reverse Warburg effect) or directly take up lactate from the
circulation (Faubert et al., 2017; Pavlides et al., 2009). Thus ,in
all these scenarios, syrosingopine-mediated trapping of lactate
in tumor cells can provide an additional bonus beyond the effect
of the drug combination on glycolysis.
There is great interest in re-positioning metformin as an
anti-cancer drug, and numerous clinical trials have been initi-
ated to assess its anti-cancer activity. Concluded trials have
reported mixed results, showing either no or weak clinical
efficacy (Kordes et al., 2015; Tsilidis et al., 2014). There is
considerable debate on the effective metformin concentration
required for anti-neoplastic activity (Chandel et al., 2016; Dow-
ling et al., 2016). The metformin concentration used in pre-
clinical models demonstrating anti-cancer activity (mM range)
is an order of magnitude greater than the serum metformin con-
centration attainable with routine anti-diabetic dosing (mM
range), suggesting that this may be partly the reason behind
the mixed results from the clinical trials. In this light, the
ability of syrosingopine to elicit synthetic lethality with metfor-
min in cancer cells and to substantially lower the effective
concentration of metformin required in cellular models (Fig-
ure S5F) may be of potential clinical benefit. As lactate trans-
port inhibition alone is at best cytostatic, this suggests that
the rational combination of an MCT1 and MCT4 inhibitor with
metformin may prove a viable anti-cancer strategy for both
drug classes.
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rabbit polyclonal MCT1 Santa Cruz sc50324; RRID: AB_2189197
Mouse monoclonal MCT1 Santa Cruz sc365501; RRID: AB_10841766
Rabbit polyclonal MCT2 Santa Cruz sc50322; RRID: AB_2187242
Rabbit polyclonal MCT3 Abcam ab60333; RRID AB_944129
Rabbit polyclonal MCT4 Santa Cruz sc50329; RRID AB_2189333
Mouse monoclonal MCT4 Santa Cruz sc376140; RRID AB_10992036
Mouse monoclonal CD147 R&D MAB972; RRID AB_2066679
Rabbit polyclonal CD147 Abcam ab64616; RRID AB_1603445
Rabbit polyclonal GAPDH Abcam ab9385; RRID AB_449791
Mouse monoclonal b1-integrin Santa Cruz sc374430; RRID AB_10991321
Chemicals, Peptides, and Recombinant Proteins
Syrosingopine Extrasynthese #1691; CAS 84-36-6
F3-Syro Custom synthesis N/A
Syro-D Custom synthesis N/A
Reserpine Sigma-Aldrich R0875; CAS 50-55-5
ARC155858 Tocris CAS 496791-37-8
Sodium oxamate Sigma-Aldrich O2751; CAS 565-73-1
Vitamin K2 Sigma-Aldrich V9378; CAS 863-61-6
NAD free acid Sigma-Aldrich NAD100-RO; CAS 53-84-9
b-NMN Sigma-Aldrich N3501; CAS 1094-61-7
Metformin Sigma-Aldrich D150959; CAS 1115-70-4
Antimycin A Sigma-Aldrich A8674; CAS 1397-84-0
Sodium fluoride Sigma-Aldrich S7920; CAS 7681-49-4
Sodium Lactate, L-[2-3H], 10-20Ci/mmol American Radiolabeled Chemicals ART 0430
Resazurin Sigma-Aldrich R7017; CAS 62758-13-8
Critical Commercial Assays
Arkray Lactate Pro 2 lactate test meter ArkRay LT-1730
pHrodo Red AM Intracellular pH Indicator Thermo Fisher Scientific P35372
NAD+/NADH Quantification Colorimetric kit BioVision K337-100
CellTiterGlo Luminescent Assay Promega G7570
Lactate-Glo Luminescent Assay Promega J5022
Experimental Models: Cell Lines
HAP1 wild-type Horizon Discovery wt line C631
HAP1 MCT1-KO cl2 Horizon Discovery HZGHC002882c002
HAP1 MCT1-KO cl10 Horizon Discovery HZGHC002882c010
HAP1 MCT4-KO cl1 Horizon Discovery HZGHC001844c001
HAP1 MCT4-KO cl10 Horizon Discovery HZGHC001844c010
HeLa ATCC CCL-2
HCT116 ATCC CCL-247
HL60 DSMZ ACC-3
K562 DSMZ ACC-10
SkBr3 Laboratory of Nancy Hynes, FMI, Basel N/A
MDA-MD-453 Laboratory of Nancy Hynes, FMI, Basel N/A
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REAGENT or RESOURCE SOURCE IDENTIFIER
Experimental Models: Organisms/Strains
Mouse: Male, 20 week old Liver-specific Tsc1/Pten double
knock-out in mixed C57BL/6J,129/SvJae,BALB/cJ background.
Michael Hall Laboratory (Hindupur et al.,
2018)
N/A
Software and Algorithms
Prism 7 GraphPad Software Version 7.0dCONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Prof.
Michael N. Hall (m.hall@unibas.ch).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mouse Liver tumor model
Liver-specific Tsc1 and Pten double-knockout mice were obtained by crossing Tsc1lox/loxmice (exons 17 and 18) with Ptenlox/loxmice
(exons 4 and 5) to transgenic mice expressing Cre recombinase under the control of the hepatocyte-specific albumin promoter (Alb-
CreTg/0) to generate liver-specific double-knockout (Tsc1lox/loxPtenlox/lox Alb-CreTg/0) mice. The mice produced were on mixed ge-
netic background (C57BL/6J, 129/SvJae, BALB/cJ). Mice were housed under temperature and humidity-controlled conditions, in a
12-h light/dark cycle with lights switched on between 0600 to 1800. All experiments were conducted on 20-week oldmale mice. In all
experiments, mice were fasted overnight before euthanasia by CO2 inhalation.
METHOD DETAILS
Cell proliferation assays
96-well plates were plated at densities of 3000 cells/150 mL medium (suspension cells) or 2000 cells/150 mL medium (adherent
cells) and growth measured after 3 (suspension cultures) or 5 days (adherent cell lines) by addition of 0.1vol resazurin (final
concentration 50 mM). The plates were incubated for several hours for resazurin conversion before fluorescent reading (535/
595nm Ex/Em) with a plate reader. After background subtraction with the medium only control, growth curves were either plotted
using non-normalized data, or was normalized to untreated control cells and expressed as percentages. Each data point was
performed in triplicate.
Immunoblotting
Cells were lysed in RIPA buffer containing protease and phosphatase inhibitors and total protein (20-40 mg) resolved on SDS-PAGE
gels. Proteins were transferred onto nitrocellulosemembranes for immunoblotting. Signals were detected with HRP-conjugated sec-
ondary antibodies and visualized with ECL detection reagent (GE Healthcare).
Co-immunoprecipitation
Cells were lysed in CHAPs buffer (120mM NaCl, 40mM HEPES pH 7.4, 50mM NaF, 1mM EDTA, 10mM b-glycerophosphate, 0.3%
CHAPS, supplemented with protease and phosphatase inhibitors). Cell lysate was pre-cleared by spinning at 20000rpm, 4C, 20mi-
nutes followed by rotation with protein A/G beads for 1 hour at 4C. 5 mg of rabbit anti-CD147 antibody (Abcam ab6416) was added to
cleared lysates and rotated overnight at 4C. Immune complexes were pulled down with protein A/G beads and washed 3x with 1ml
CHAPS buffer. Proteins were eluted with 0.1M glycine (pH 3) and resolved on SDS-PAGE gels. Target proteins were detected by
immunoblotting with the following mouse monoclonal antibodies: CD147 (R&D MB972), MCT1 (Santa Cruz sc365501) and MCT4
(Santa Cruz sc376140).
DARTS assay
HCT116 cells were grown to 80%confluency in DMEMand pre-treated with compounds (10 mM) for 2 hours. After washing with PBS,
cytosolic depletion was performed by scraping cells and incubating with 1.9ml digitonin buffer (digitonin 0.01%, NaCl 150mM,
HEPES 50mM pH 7.4) for 30 minutes on ice before centrifugation (2000 g, 10 minutes, 4C). Cell pellets were solubilized with
400 mL lauryl maltoside buffer (lauryl maltoside 1%, NaCl 150mM, HEPES 50mM pH 7.4) for 3 hours on ice and centrifuged at
10000 g, 10 minutes, 4C. Protein concentration was adjusted to 2mg/ml protein with lauryl maltoside buffer and treated with com-
pounds (10 mM) overnight on ice. Digestion with thermolysin (Roche, P1512) was performed in a V-bottom 96-well plate (1ng ther-
molysin/mg protein) with shaking for 30 minutes at 37C. Digestion was stopped by addition of 2x SDS-PAGE buffer and samplese2 Cell Reports 25, 3047–3058.e1–e4, December 11, 2018
were resolved on SDS-PAGE gels and probed for MCT1 (Santa Cruz, sc-50324), MCT4 (Santa Cruz, sc-50329), CD147 (Santa Cruz,
sc-13976) and b-1 integrin (Santa Cruz, sc-374430).
Mouse experiments
Animal experiments were performed in accordance with the federal guidelines for animal experimentation and were approved by the
Kantonales Veterina¨ramt of Kanton Basel-Stadt. Mice were injected intra-peritoneally with syrosingopine (7.5mg/kg body weight)
16 hours and 1 hour before sacrifice. Mice were euthanized with CO2 and blood taken from the body cavity for lactate measurement.
Serum lactate levels were measured using an Arkray Lactate Pro 2 lactate test meter with corresponding test strips. Intracellular
lactate was measured in liver tumor nodules. Nodules were excised (3 per mouse) and ground to a fine powder in liquid nitrogen.
Pulverized tumor material was resuspended in 20 mL water and freeze-thawed 3 times (dry-ice/37 water bath) to release cell con-
tents. Lactate was measured with the lactate test meter. Protein concentration was measured by BCA to normalize the lactate mea-
surements between the nodules.
ATP and lactate measurement
ATP levels were measured by lysing cells with CellTiterGlo reagent (Promega) and measuring released luminescence with a lumin-
ometer. Experiments were set up in 96-well format (variable cell numbers/100 mLmedium) and at the desired time-point, ATP content
was determined with 100 mL CellTiterGlo Reagent.
Lactate levels were measured enzymatically in 96-well plates according to manufacturer’s specifications (Lactate-Glo Assay,
Promega, J5022). 15000 cells/well or 30000 cells/well were seeded respectively for HeLa and HAP1. After compound incubation,
cells were washed with PBS and lysed with 22.5 mL HCl (0.2N). Cell lysates were neutralized with 7.5 mL 1M Tris-base and incubated
with 30 mL detection reagent. Luminescence was recorded after 1 hour and intracellular lactate concentrations determined from a
standard curve. Extracellular lactate production was measured in the medium with background subtraction from fresh medium.
Lactate levels were normalized to protein content (Pierce BCA, 23225) from duplicate plates after lysing cells with NP40 (1% v/v).
Alternatively, lactate levels were alsomeasured using an Arkray Lactate Pro 2 lactate test meter with corresponding test strips. Extra-
cellular lactate wasmeasured directly from culturemedium. 500,000 cells were seeded in 2ml medium and incubated for 6 hours with
drug treatments as indicated. Intracellular lactate was measured from the cell pellet. Cells were spun down by touch-spin and resus-
pended in 20 mL dH2O. The pellet was lysed by freeze-thawing 3x in a dry-ice/water bath and the released lactate measured.
Intracellular pH measurement
Intracellular pHwas determinedwith pHrodoRedAM (Thermo Fisher Scientific, P35372). HeLa cells grown in DMEM (FCS 10%)were
seeded in 96-well plates (2000 cells/well) and medium replaced after 24 hours with DMEM buffered with HEPES 20mM pH 7.0-7.6
(Sigma), FCS 1%. After drug treatment, cells were washed with HBSS, HEPES 20mM and labeled with pHrodo Red AM dye for
30 minutes. After washing with HBSS, HEPES 20mM, cell fluorescence was measured (560/585 Ex/Em) and intracellular pH deter-
mined according to calibration standards (Thermo Fisher Scientific, P35379).
Radiolabeled lactate uptake and export assays
Lactate export: Cells were counted and seeded at a density of 2x106 cells per ml in RPMI1640medium.Mediumwas adjusted to pH6
to favor uptake of exogenous lactate, particularly for MCT1-KO cells. Radioactive L-lactate (American Radiolabeled Chemicals,
ART0430, 1mCi/ml) was added (2 mCi per sample) to cells at 37 for 60minutes. Drugs were added for the final 30minutes of labeling.
Based on pilot experiments which showed a rapid initial efflux of labeled lactate after washing the cells, a drug pre-treatment of
30 minutes was held to be optimal to allow time for drug-mediated inhibition before performing the lactate export assays. At the
end of pulse labeling (60 minutes), cells were spun down (2000rpm, 5 minutes), washed once with 1ml ice-cold RPMI1640 medium
(pH 6) and resuspended in fresh ice-cold, label-free RPMI1640 medium (pH 7.4 and containing the respective drug according to the
experiment) and kept on ice. At appropriate time points, the cell suspension was sampled (2x106 cells per sampling). Cells were
quickly pelleted by touch-spin and separated into cell pellet and supernatant. The pellet was lysed with 500 mL 0.1M HCl and radio-
activity in 450 mL of lysed pellet measured in 10ml of scintillation fluid in a scintillation counter to determine the amount of radioactivity
retained in the cell. Radioactivity in the supernatant was also counted by scintillation counting to determine how much radioactivity
was exported out of the cells into the supernatant over time.
Lactate uptake: Cells were labeled and drug-treated similar to the export assay. At the end of the pulse/drug-treatment (60/30 mi-
nutes), cells were spun down (2000rpm 5 minutes), briefly rinsed and the cell pellet was lysed with 500 mL 0.1M HCl. Radioactivity in
450 mL of lysed pellet was measured in 10ml of scintillation fluid in a scintillation counter to determine the amount of radioactivity
present in the cell. As the transporters work in both directions, measuring the amount of radioactivity present in the cell after a 60min-
ute pulse shows the equilibrium reached between lactate import and export.
NAD+/NADH measurements
Total NAD (NADt) and NADH levels were measured using a NAD/NADH Quantitation Colorimetric Kit (Biovision). Cells were
seeded (3-5x105 cells/5ml in full medium. At the end of drug treatment period, cells were harvested and the pellets processed
according to the kit instructions. NADt (NAD1 and NADH) levels were measured were read at OD 450nm. NADH was determinedCell Reports 25, 3047–3058.e1–e4, December 11, 2018 e3
by decomposing NAD+ at 60, 30 mins before performing detection reaction. NADt and NADH readings were normalized to protein
content of the cell lysate. NAD+/NADH ratio was determined from the measured NADt and NADH values by the following formula:
(NADt-NADH)/NADH.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis was performed using Prism7 (ver 7.0d, GraphPad software). Statistical tests of data were either two-tailed
unpaired Mann-Whitney test (Figures 1A and 1B), or two-tailed unpaired Students’s ‘t’-test (all other analyses). Replicate information
is indicated in the figure legends.e4 Cell Reports 25, 3047–3058.e1–e4, December 11, 2018
